HAVAS HEALTH NETWORK LAUNCHES ITS GLP-1 CONSULTANCY IN PARIS WITH "SHAPE SHIFTING" EVENT ON HEALTH AND WELLNESS

The network is bringing together thought leaders, branding experts, and healthcare professionals in their Paris Village to explore the latest transformational impact of GLP-1 treatments emerging and disrupting the European market.

PARIS, March 6, 2025 /CNW/ - Havas Health Network is launching its groundbreaking GLP-1 consultancy in Europe with flagship event, "Shape Shifting: A Close Look at the Health and Wellness Disruptor – GLP-1," on March 13^th at the Havas Village in Paris.

Positioned at the nexus of health, creativity, and technology, this initiative underscores Havas' commitment to innovation, offering unique first mover thinking to clients, industry partners, and brand marketers navigating the rapidly growing GLP-1 space.

Promotional graphic for “Shape Shifting,” a Havas GLP-1 Consultancy event exploring the health and wellness disruptor GLP-1. The event is scheduled for Thursday, March 13, from 17:30 to 19:00. The design features bold white typography on a black background, with futuristic imagery, including an aerial cityscape, a green-tinted close-up of an eye, and abstract organic shapes. (CNW Group/Havas Health Network)

Inspired by the success of GLP101 Day, organized by Havas in New York last November, this European-focused event will unite thought leaders and industry professionals to explore the science behind GLP-1s and their transformative impact on healthcare and consumer markets. Through this next event, Havas Health Network aims to provide regional European brand and marketing leaders with actionable insights to navigate and capitalize on this global revolution and its impact from a market perspective.

GLP-1s have revolutionized the health and wellness industry and are consequently reshaping consumer behaviors and habits beyond just weight loss and diabetes. In the U.S., these medications are disrupting businesses across the healthcare and broader consumer goods and lifestyle industries. Forecasts predict that the global GLP-1 market will reach $5.56 billion USD by 2030 due to new drug launches and the rising prevalence of diabetes across high-income countries.*

"The North American and European markets, while similar, have unique cultural nuances that will impact treatment adoption and engagement beyond healthcare," said Chloé Depiesse, Managing Director – Havas Health Network. "Additional insights from Europe allow us to refine our approach, meeting local needs while staying ahead of the curve in this rapidly evolving space."

"With our strong network and understanding of the evolving GLP-1 space, we are committed to delivering innovative solutions that meet the emerging demands of the European market," said Anna Maria Marra, CEO – Europe, Havas Health Network. "Our goal is to engage and educate clients and partners on GLP-1 treatments and their growing applications across Europe."

For more on Havas Health Network's GLP-1 Consultancy offering and how your brand can navigate this new landscape, click here.

For access to Havas' proprietary GLP-1 Prosumer Report, click here.

About Havas Health Network:

Havas Health Network unites Havas Life, Havas Lynx, and Jacques, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Network. The network's approach is centered around making a meaningful difference and has the talent, tenacity, and technology that health companies, brands, and people need to thrive in today's world. For more information, visit www.HavasHealth.com. 

*Reference: Mordor Intelligence, Report: Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market Source 

SOURCE Havas Health Network

Press Contacts: Payton Green, VP of Global Communications, Havas Health & Creative Networks, [email protected]; Sahra Brault, Account & Growth Director, Havas Life Paris, [email protected]